Target Name: NPY4R2
NCBI ID: G100996758
Review Report on NPY4R2 Target / Biomarker Content of Review Report on NPY4R2 Target / Biomarker
NPY4R2
Other Name(s): Neuropeptide Y receptor type 4 | NPY4R_HUMAN | PP1 | PPYR1 | Neuropeptide Y receptor type 4-2 | Neuropeptide Y receptor Y4-2, transcript variant 1 | Pancreatic polypeptide receptor 1 | neuropeptide Y receptor Y42 | neuropeptide Y receptor Y4-2 | NPY4-R | neuropeptide Y receptor type 4-like | NPY4R2 variant 1 | CH17-360D5.1 | NPY4R

The Neurotransmitter NPY4R2: A Promising Drug Target and Biomarker for Depression

Abstract:

Neurotransmitter serotonin (NPY) plays a crucial role in regulating mood, appetite, and sleep. Imbalances in NPY levels have been associated with various psychiatric disorders, including depression. The neurotransmitter NPY4R2 has been identified as a promising drug target and biomarker for depression. This article reviews the current understanding of NPY4R2 and its potential as a drug target for the treatment of depression.

Introduction:

Depression is a common and debilitating mental disorder that affects millions of people worldwide. According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and its prevalence is expected to increase in the coming years due to the aging population and increasing lifespan. The symptoms of depression can range from low mood and energy to severe anxiety and suicidal thoughts. While several medications are available for the treatment of depression, the majority of these medications have limited efficacy and potential side effects.

NPY4R2: A Potential Drug Target and Biomarker for Depression

The neurotransmitter serotonin (NPY) plays a crucial role in regulating mood, appetite, and sleep. It is produced by the neurotransmitter system and is involved in the regulation of various physiological processes, including mood, appetite, and sleep. Imbalances in NPY levels have been associated with various psychiatric disorders, including depression.

The neurotransmitter NPY4R2 has been identified as a promising drug target and biomarker for depression. NPY4R2 is a potent modulator of NPY activity and has been shown to play a role in the regulation of mood, appetite, and sleep. Studies have shown that individuals with depression have lower levels of NPY4R2 than healthy individuals. Additionally, individuals with major depressive disorder (MDD) have lower levels of NPY4R2 compared to those with depression without major depressive disorder (MDD).

NPY4R2 has been shown to play a role in the regulation of neurotransmitter systems involved in mood regulation, including dopamine (DA), norepinephrine (NE), and GABA. It has been shown to increase the levels of neurotransmitters involved in mood regulation, such as DA and NE, and to decrease the levels of GABA, which is involved in the regulation of anxiety and depression.

In addition to its role in neurotransmitter regulation, NPY4R2 has also been shown to play a role in the regulation of pain perception. Studies have shown that individuals with depression have increased pain perception compared to healthy individuals. Additionally, individuals with MDD have increased pain perception compared to those with MDD without major depressive disorder.

Potential Therapeutic Strategies for NPY4R2:

Given the potential role of NPY4R2 in the regulation of mood, appetite, and sleep, as well as its involvement in pain perception, there is significant potential for the development of drugs that target NPY4R2 as a therapeutic strategy for depression.

One approach to targeting NPY4R2 is to develop compounds that modulate its activity. This can be done through various methods, includingSite-Directed Amino Acid Mutagenesis (SDAM), which allows for the rapid and specific modification of specific amino acids within the protein sequence. By modulating the activity of NPY4R2, researchers can develop drugs that target the underlying mechanisms of depression.

Another approach to targeting NPY4R2 is to develop compounds that modulate its synthesis or degradation. This can be done through various methods, including inhibition of the enzyme cyclic ADP-ribose synthase (CARDS) or the enzyme parkin, which are involved in the synthesis of NPY4R2. By modulating the synthesis or degradation of NPY4R2, researchers can develop drugs that reduce its levels and improve the effectiveness of existing antidepressants.

In addition to targeting its synthesis and degradation, researchers can also develop compounds that modulate its activity through its interactions with other neurotransmitters involved in depression. This can be done by modulating the activity of neurotransmitters involved in

Protein Name: Neuropeptide Y Receptor Y4-2

Functions: G protein-coupled receptor for PPY/pancreatic polypeptide/PP, NPY/neuropeptide Y and PYY/peptide YY that is negatively coupled to cAMP. The rank order of affinity for these polypeptides and their derivatives is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34] NPY > NPY > PYY (3-36) and NPY (2-36) > PP (13-36) > PP (31-36) > NPY free acid

The "NPY4R2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPY4R2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1 | NRXN3 | NSA2 | NSA2P2 | NSD1 | NSD2 | NSD3 | NSDHL | NSF | NSFL1C | NSFP1 | NSG1 | NSG2 | NSL complex | NSL1 | NSMAF | NSMCE1 | NSMCE1-DT | NSMCE2 | NSMCE3 | NSMCE4A | NSMF | NSRP1 | NSUN2 | NSUN3 | NSUN4 | NSUN5 | NSUN5P1 | NSUN5P2